drugset / Trial / NCT00725582

Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild Asthma

NCT00725582 ↗

Phase 1 Completed 24 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the effect of IMA-026, an antibody to IL-13, on airway hyperresponsiveness and airway inflammation in mild asthmatics. IMA-026 will be given as 2 injections under the skin 1 week apart at 2 mg/kg each dose. The study will include a screening period and a treatment period which includes doses on day 1 and day 8.

Timeline

Start
2008-09
Primary completion
2009-06
Completion
2009-06

Outcome

Missed primary endpoint

paper Treatment with IMA-026 did not attenuate the asthmatic responses on Day 14 or Day 35. PMID 21057005 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject IMA-026 Unknown 2 mg/kg Subcutaneous

Indications